Table 1.
List of the OC-PDXs with the pharmacological and molecular parameters studied.
| #ID PDXs | DDP response | OLA response | BRCA1/2 status | BRCA1 promoter methylation | HRDetect score | % RAD51+/GMN+ cells | % γH2AX+/GMN+ cells | HR status |
|---|---|---|---|---|---|---|---|---|
| MNHOC511 | VS | VS | BRCA1 mut | 0% | 0% | 70% | HRD | |
| MNHOC513 | VS | VS | BRCA1 mut | 0% | 0% | 84% | HRD | |
| MNHOC218 | VS | VS | 0% | 0% | 52% | |||
| MNHOC106 | S | BRCA1 mut | 0% | 0% | 94% | HRD | ||
| MNHOC78 | S | BRCA1 mut | 0% | 0% | 58% | HRD | ||
| MNHOC508 | VS | VS | BRCA2 mut | 0% | 1% | 68% | HRD | |
| MNHOC212 | VS | wt | 100% | 0.999 | 1% | HRD | ||
| MNHOC107 | S | BRCA1 mut | 0% | 2% | 100% | HRD | ||
| MNHOC109 | S | wt | 0% | 2% | 88% | |||
| MNHOC154 | S | BRCA1 mut | 0% | 0.999 | 2% | 60% | HRD | |
| MNHOC76 | R | R | wt | 0% | 2% | 90% | ||
| MNHOC230 | VS | wt | 0% | 0.999 | 3% | HRD | ||
| MNHOC241 | VS | 0% | 3% | 80% | ||||
| MNHOC9 | S | 0% | 3% | |||||
| MNHOC500 | VS | VS | BRCA1 mut | 0% | 4% | 30% | HRD | |
| MNHOC8Y | R | wt | 100% | 4% | 53% | HRD | ||
| MNHOC271 | S | S | 0% | 6% | 66% | |||
| MNHOC266ddpR | R | R | 4% | 7% | 84% | |||
| MNHOC8 | VS | VS | wt | 84% | 20% | 45% | HRD | |
| MNHOC124ddpR | R | R | wt | 0% | 0.119 | 22% | 82% | |
| MNHOC506 | VS | R | wt | 0% | 22% | 66% | ||
| MNHOC143 | S | R | wt | 0% | 26% | 20% | ||
| MNHOC111/2C | R | wt | 0% | 28% | 68% | |||
| MNHOC18 | S | R | wt | 0% | 32% | 76% | ||
| MNHOC84 | R | R | wt | 0% | 32% | 76% | ||
| MNHOC239 | S | R | wt | 0% | 0.075 | 38% | 32% | |
| MNHOC94/2C | R | R | wt | 0% | 38% | 66% | ||
| MNHOC239ddpR | R | R | wt | 0% | 0.156 | 40% | 58% | |
| MNHOC125 | S | BRCA1 mut | 0% | 40% | 98% | HRD | ||
| MNHOC119 | R | wt | 0% | 40% | 78% | |||
| MNHOC22 | VS | R | BRCA1 mut | 0% | 40% | 74% | HRD | |
| MNHOC142 | S | 0% | 40% | 78% | ||||
| MNHOC518 | VS | VS | 93% | 41% | HRD | |||
| MNHOC10 | R | wt | 0% | 42% | ||||
| MNHOC316 | VS | R | 0% | 45% | ||||
| MNHOC315 | R | R | 0% | 45% | ||||
| MNHOC164 | S | 0% | 56% | 9% | ||||
| MNHOC258 | S | 0% | 58% | 90% | ||||
| MNHOC266 | VS | R | BRCA1 mut | 0% | 0.991 | 58% | 96% | HRD |
| MNHOC503 | S | 0% | 62% | 80% | ||||
| MNHOC124 | VS | R | wt | 0% | 0.014 | 66% | 92% | |
| MNHOC182 | R | R | wt | 0% | 70% | 52% | ||
| MNHOC261 | VS | wt | 0% | 0.018 | 78% | |||
| MNHOC94/2TR | R | R | wt | |||||
| MNHOC135 | S | wt | 0% | 0.999 | HRD | |||
| MNHOC520 | S | R | 49% | |||||
| MNHOC79 | R | wt | 0% |
HGOC high-grade ovarian cancer, LG low-grade ovarian cancer, s.c. subcutaneous, i.p. intraperitoneal, DDP cisplatin, OLA olaparib, VS very sensitive, S sensitive, R resistant, mut mutated, wt wild type, HRD homologous recombination deficiency.